Why is Medicamen Biotec falling/rising?

As of 30-Jul, Medicamen Biotech Ltd's stock price is currently at Rs 400.00, reflecting an increase of Rs 20.05, or 5.28%. The stock has shown a trend reversal by gaining after two consecutive days of decline and has outperformed its sector by 4.94% today. The stock reached an intraday high of Rs 405.1, indicating positive momentum. However, despite this short-term gain, the stock has underperformed over the longer term, with a year-to-date decline of 21.45% and a 3-year decline of 48.86%. The company's financial health is concerning, as it has reported a low return on capital employed (ROCE) of 5.30% and a significant drop in operating profit over the last five years, which may deter long-term investors.
In the broader market context, while Medicamen Biotech's stock has risen in the short term, the benchmark Sensex has seen a decline of 1.50% over the past week, highlighting the stock's relative strength in a challenging market. However, the company's long-term performance remains weak, with a 1-year return of -9.04% compared to the Sensex's slight gain of 0.03%. The lack of investment from domestic mutual funds, which hold 0% of the company, suggests a lack of confidence in its future prospects. Overall, while the recent price increase may attract some attention, the underlying financial issues and consistent underperformance against benchmarks indicate that caution is warranted for potential investors.